| Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors G Guaraldi, N Squillace, C Stentarelli, G Orlando, R D'Amico, G Ligabue, ... Clinical Infectious Diseases 47 (2), 250-257, 2008 | 288 | 2008 |
| Cardiovascular risk and dyslipidemia among persons living with HIV: a review P Maggi, A Di Biagio, S Rusconi, S Cicalini, M D’Abbraccio, G d’Ettorre, ... BMC infectious diseases 17, 1-17, 2017 | 166 | 2017 |
| Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial F Perrone, MC Piccirillo, PA Ascierto, C Salvarani, R Parrella, AM Marata, ... Journal of translational medicine 18 (1), 405, 2020 | 146 | 2020 |
| Weight gain: a possible side effect of all antiretrovirals L Taramasso, E Ricci, B Menzaghi, G Orofino, S Passerini, G Madeddu, ... Open forum infectious diseases 4 (4), ofx239, 2017 | 99 | 2017 |
| The NLRP3 inflammasome is upregulated in HIV-infected antiretroviral therapy-treated individuals with defective immune recovery A Bandera, M Masetti, M Fabbiani, M Biasin, A Muscatello, N Squillace, ... Frontiers in immunology 9, 329208, 2018 | 89 | 2018 |
| Sexual dysfunction in HIV-infected men: role of antiretroviral therapy, hypogonadism and lipodystrophy G Guaraldi, K Luzi, R Murri, A Granata, MD Paola, G Orlando, N Squillace, ... Antiviral therapy 12 (7), 1059-1066, 2007 | 87 | 2007 |
| Lipodystrophy and quality of life of HIV-infected persons G Guaraldi, R Murri, G Orlando, N Squillace, C Stentarelli, S Zona, ... Aids Rev 10 (3), 152-161, 2008 | 72 | 2008 |
| Body image is a major determinant of sexual dysfunction in stable HIV-infected women K Luzi, G Guaraldi, R Murri, M De Paola, G Orlando, N Squillace, ... Antiviral therapy 14 (1), 85-92, 2009 | 70 | 2009 |
| Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir P Bonfanti, G Madeddu, R Gulminetti, N Squillace, G Orofino, P Vitiello, ... Aids 31 (3), 455-457, 2017 | 66 | 2017 |
| Severity of lipodystrophy is associated with decreased health-related quality of life G Guaraldi, R Murri, G Orlando, C Giovanardi, N Squillace, M Vandelli, ... AIDS patient care and STDs 22 (7), 577-585, 2008 | 65 | 2008 |
| Multidisciplinary approach to the treatment of metabolic and morphologic alterations of HIV-related lipodystrophy G Guaraldi, G Orlando, N Squillace, G De Santis, A Pedone, A Spaggiari, ... HIV clinical trials 7 (3), 97-106, 2006 | 64 | 2006 |
| Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large … L Taramasso, P Tatarelli, E Ricci, G Madeddu, B Menzaghi, N Squillace, ... BMC Infectious Diseases 18, 1-8, 2018 | 58 | 2018 |
| Factors associated with weight gain in people treated with dolutegravir L Taramasso, P Bonfanti, E Ricci, G Orofino, N Squillace, B Menzaghi, ... Open Forum Infectious Diseases 7 (6), ofaa195, 2020 | 56 | 2020 |
| Changes in subcutaneous adipose tissue microRNA expression in HIV-infected patients N Squillace, E Bresciani, A Torsello, A Bandera, F Sabbatini, ... Journal of Antimicrobial Chemotherapy 69 (11), 3067-3075, 2014 | 39 | 2014 |
| Clusterization of co-morbidities and multi-morbidities among persons living with HIV: a cross-sectional study P Maggi, CR Santoro, M Nofri, E Ricci, N De Gennaro, C Bellacosa, ... BMC infectious diseases 19, 1-9, 2019 | 36 | 2019 |
| Factors associated with hospital admission for COVID-19 in HIV patients A Di Biagio, E Ricci, L Calza, N Squillace, B Menzaghi, S Rusconi, ... Aids 34 (13), 1983-1985, 2020 | 35 | 2020 |
| Detectable HIV viral load is associated with metabolic syndrome N Squillace, S Zona, C Stentarelli, G Orlando, B Beghetto, G Nardini, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 52 (4), 459-464, 2009 | 33 | 2009 |
| Long-term psychometric outcomes of facial lipoatrophy therapy: Forty-eight–week observational, nonrandomized study G Orlando, G Guaraldi, D De Fazio, A Rottino, A Grisotti, M Blini, ... AIDS Patient Care and STDs 21 (11), 833-842, 2007 | 32 | 2007 |
| The effect of switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) on liver enzymes, glucose, and lipid profile N Squillace, E Ricci, B Menzaghi, GV De Socio, S Passerini, C Martinelli, ... Drug Design, Development and Therapy, 5515-5520, 2020 | 31 | 2020 |
| Glomerular filtration rates in HIV-infected patients treated with and without tenofovir: a prospective, observational study G Guaraldi, A Roverato, C Giovanardi, F Ravera, N Squillace, G Orlando, ... Journal of antimicrobial chemotherapy 63 (2), 374-379, 2009 | 25 | 2009 |
